Price$10.53-0.14 (-1.31%)
01:30 PM07:45 PM
News · 26 weeks50-93%
2025-10-262026-04-19
Mix1890d
- Insider7(39%)
- SEC Filings5(28%)
- Other3(17%)
- Analyst2(11%)
- Offering1(6%)
Latest news
25 items- ANALYSTCanaccord Genuity initiated coverage on Biohaven with a new price targetCanaccord Genuity initiated coverage of Biohaven with a rating of Buy and set a new price target of $21.00
- INSIDERSEC Form 4 filed by Mehta Kishan4 - Biohaven Ltd. (0001935979) (Issuer)
- PRBiohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentPhase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations; it has also demonstrated a highly favorable safety and tolerability profile in more than 700 trial participants.In nonclinical studi
- SECSEC Form DEFA14A filed by Biohaven Ltd.DEFA14A - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form DEF 14A filed by Biohaven Ltd.DEF 14A - Biohaven Ltd. (0001935979) (Filer)
- INSIDERAmendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)4/A - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Buten Matthew4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Clinical Operations Gentile Kimberly4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by VP, Chief Accounting Officer Clark George C.4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Car Bruce4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Coric Vlad4 - Biohaven Ltd. (0001935979) (Issuer)
- SECBiohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form S-8 filed by Biohaven Ltd.S-8 - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form 10-K filed by Biohaven Ltd.10-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial ResultsPrioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity:Inflammation and Immunology:Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of Ig
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
- ANALYSTGoldman initiated coverage on Biohaven with a new price targetGoldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00
- ANALYSTBiohaven upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00
- SECBiohaven Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare ConferenceReports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date:IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing of
- INSIDERSVP, Clinical Operations Gentile Kimberly covered exercise/tax liability with 1,956 shares and converted options into 3,750 shares, increasing direct ownership by 2% to 99,557 units (SEC Form 4)4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERChief Financial Officer Buten Matthew converted options into 4,250 shares and covered exercise/tax liability with 2,594 shares, increasing direct ownership by 0.85% to 195,652 units (SEC Form 4)4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERChief Executive Officer Coric Vlad converted options into 14,250 shares and covered exercise/tax liability with 7,430 shares, increasing direct ownership by 0.38% to 1,803,968 units (SEC Form 4)4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERChief Scientific Officer Car Bruce converted options into 4,750 shares and covered exercise/tax liability with 2,381 shares, increasing direct ownership by 44% to 7,715 units (SEC Form 4)4 - Biohaven Ltd. (0001935979) (Issuer)